Hi,
I have HCC and just got my latest MRI. Recent ablation efforts seem to be successful on the known tumor.
I will be seeing one of my oncologists the 27th to discuss these results, but I was hoping for some information regarding the significance of the possible THID that is mentioned before that.
My labs look pretty good: AFT 9.5 / AST 35 / Ammonia 26, however my ALT is up a bit 54 and so is my bilirubin 1.6 (MELD=8).
I had my gall bladder removed, as well as RF ablation and ethanol ablation on 8/2/2013. Prior to that 2 DEB-TACE's.
Thank you very much in advance !
Here is the report:
MRI LIVER W WO CONTRAST
CPT:74183Accession#:5681688PRV
MRI ABDOMEN COMBINED
INDICATION: Hepatoma status post ethanol ablation and RF ablation.
Followup evaluation.
COMPARISON: 30 August 2013.
TECHNIQUE: Multiplanar T1, T2 and diffusion weighted images of the
abdomen were obtained without and with IV contrast. 10 mL of Gadavist
was administered intravenously.
FINDINGS: The liver has a nodular surface consistent with cirrhosis.
The medial left lobe of the liver shows atrophy and contains a stable
nonenhancing mass representing the ablation site. There is an area of
heterogeneous hyperenhancement in the dome of the liver adjacent to the
ablation site which is only seen in the arterial phase of contrast
imaging. Otherwise, no new hepatic lesions are identified. The portal
venous system is patent. There is no dilatation of the biliary tree.
The gallbladder is absent. The pancreas, spleen, kidneys, adrenals and
abdominal aorta are within normal limits. There is no free fluid or
lymphadenopathy.
IMPRESSION:
Stable ablation site in the atrophic medial left lobe of the liver.
Area of heterogeneous enhancement adjacent to the ablation site may
represent a transient hepatic intensity difference (THID). Eovist
should be used if followup evaluation by MRI is indicated.
SQR